DOLBY LABORATORIES, INC. (DLB) FY2026 Q3 P&L / Income Statement
2026-03-28 to 2026-06-26
Revenue by Product and Service (6 categories)
2026-03-28 to 2026-06-26
Swipe to see the full flow
Chart details
DOLBY LABORATORIES, INC. (DLB) FY2026 Q3 P&L / Income Statement
Income statement for 2026-03-28 through 2026-06-26. View: Product and service (6 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenue
- 304,995,000 US dollars
- Total cost of revenue
- 40,319,000 US dollars
- Gross profit
- 264,676,000 US dollars
- Total operating expenses
- 230,360,000 US dollars
- Operating income
- 34,316,000 US dollars
- Total other income
- 9,486,000 US dollars
- Income before income taxes
- 43,802,000 US dollars
- Provision for income taxes
- 14,588,000 US dollars
- Net income including noncontrolling interest
- 29,214,000 US dollars
- Products and services
- 22,644,000 US dollars
- Broadcast
- 106,579,000 US dollars
- Mobile
- 51,010,000 US dollars
- Licensing, CE Revenue
- 31,506,000 US dollars
- Licensing, PC Revenue
- 28,343,000 US dollars
- Other
- 64,913,000 US dollars
- Research and development
- 65,749,000 US dollars
- General and administrative
- 75,585,000 US dollars
- Restructuring charges
- 3,955,000 US dollars
- Sales and marketing
- 85,071,000 US dollars
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to DOLBY LABORATORIES, INC.: $28.60 M; to noncontrolling interests: $612.00 K.

Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
86.8%
Gross profit / revenue
Operating margin
11.3%
Operating profit / revenue
Cash conversion
573.2%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!
